







4Q/ FY 2022 Results Presentation

24 February 2023

Revenue	Profit Before Tax (PBT)	Net Profit ¹	EPS ²
S\$3,863.7m	S\$448.9m	S\$369.6m	126.8 cents
 24.3% YoY	 24.8% YoY	 18.4% YoY	 18.5% YoY

PBT Margin	Net Profit Margin	NAV/ Share
FY2022: 11.6%	FY2022: 9.6%	S\$9.76
FY2021: 11.6%	FY2021: 10.0%	31 Dec 2021: S\$9.35

1. Net Profit refers to Profit attributable to Owners of the Company
2. Earnings per share (EPS) is on a fully diluted basis

FY2022 vs FY2021

Portfolio A

1. Life Science, Genomics, Molecular Diagnostics and Related Materials Technology
2. Medical Devices and Equipment
3. Healthcare & Wellness Technology, Lifestyle Consumer Tech, Health Improvement Products and Others

 **31.9%**

Overall Portfolio A Revenue

\$S\$1.7B

Portfolio B Revenue

4. Instrumentation, Test & Measurement Technology
5. Networking & Communications, Security & Safety, Building Automation, Industrial IOT
6. Advanced Payment Systems
7. Advanced Industrial Technology, Computing & Productivity Systems, Printing & Imaging, Related Components Technology and Others


 **18.9%**

Overall Portfolio B Revenue


\$S\$2.2B

 Diversified across more than 100 customers

Revenue (S\$m)



Net Profit (S\$m)





FINANCIAL PERFORMANCE REVIEW

(S\$m)	FY2022	FY2021	YoY (%)
Revenue	3,863.7	3,107.5	24.3
Profit Before Tax (PBT)	448.9	359.6	24.8
PBT Margin (%)	11.6	11.6	-
Income tax expense	78.8	47.3	66.7
Effective Tax Rate (%)	17.6	13.1	-
Net profit	369.6	312.1	18.4
Net Margin (%)	9.6	10.0	-
EPS (cents)	126.8	107.0	18.5

- Strongest revenue growth seen in Healthcare & Wellness, Life Science & Genomics and Instrumentation, Test & Measurement technology domains.
- Despite cost pressures, PBT rose 24.8% YoY to S\$448.9m with PBT margin maintained at 11.6%.

(S\$m)	4Q 2022	4Q 2021	YoY (%)
Revenue	1,045.0	905.4	15.4
Profit Before Tax (PBT)	117.2	109.7	6.9
PBT Margin (%)	11.2	12.1	-
Income tax expense	(19.0)	(14.8)	28.5
Effective Tax Rate (%)	16.3	13.5	-
Net profit	98.0	94.6	3.5
Net Margin (%)	9.4	10.5	-
EPS (cents)	33.6	32.5	3.4

- Strongest revenue growth seen in Instrumentation, Test & Measurement, Healthcare & Wellness and Life Science & Genomics technology domains.
- Despite cost pressures, PBT rose 6.9% YoY to S\$117.2m with PBT margin remaining healthy at 11.2% in 4Q 2022.




FINANCIAL POSITION AND CASH FLOW


(S\$m)	31 December 2022	31 December 2021
Cash & Bank Balances	812.6	807.9
Net Current Assets	1,939.8	1,830.0
Net Non Current Assets	903.1	889.4
Total Net Assets	2,842.9	2,719.5
Accumulated Profits	2,098.4	1,948.3
Share Capital & Reserves	741.3	768.0
Non-Controlling Interests	3.2	3.1
Total Equity	2,842.9	2,719.5
Net Asset Value per share	S\$9.76	S\$9.35

As at 31 December 2022, Venture remains in a net cash position with no bank borrowings.

NAV per share rose 4.4% YoY to S\$9.76 as at 31 December 2022.


(S\$m)	31 December 2022	31 December 2021
Trade Receivables	906.4	829.2
Trade Payables	(533.1)	(643.6)
AR- AP	373.2	185.7
Inventories	1,065.3	1,049.4
Working Capital	1,438.5	1,235.1

-  Proactive inventory management and continuous resolution of supply chain challenges - Inventory levels held steady versus the same period last year, but fell 15.0% QoQ (30 September 2022: S\$1,253.1 million).



**PROPOSED
FINAL
DIVIDEND**

▼ The Board of Directors has declared a final dividend of **S\$0.50 per share** on a one-tier tax-exempt basis, bringing the full year dividend to S\$0.75 per share.



Key Dates

▼ Book Closure: 9 May 2023

▼ Payment: 23 May 2023



OUTLOOK



Venture continued its growth momentum into the final quarter of fiscal year 2022, delivering a full year result that exceeds market expectations.

In the short term, the global macroeconomic and geopolitical environment remain uncertain. Notwithstanding these uncertainties, Venture continues to keep a sharp focus on deepening its partnerships with customers to create outstanding innovative products and services, and to scale up its businesses.

Venture will invest in the development of new differentiating capabilities in multiple technology domains to stay uniquely relevant and immensely impactful. The Group will continue to enhance its human capital, including strategic hires, to ascend new heights and attain its long-term objectives of creating value for all stakeholders.

This presentation may contain certain forward-looking statements including, but not limited to, statements as to future operating results and plans.

These statements are based on our assumptions and estimates and are subject to known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Group to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements.

Consequently, readers are cautioned not to place undue reliance on any forward-looking statements.



Thank You

For enquiries, please contact:

Judy Tan

Investor Relations & Corporate Communications

+65 6484 8136

judy.tan-th@venture.com.sg